Cancer Care Ontario | Action Cancer Ontario

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

863 Results

Guidelines and Advice

Exercise for People with Cancer

Status: Current
ID: 19-5
Version: 2

Jul 2024

Guidelines and Advice

Organizational Standards for Diagnostic Assessment Programs

Status: Archived
ID: DAP

Dec 1969

Guidelines and Advice

Establishing Comprehensive Cancer Patient Education Services

Status: Archived
ID: 20-1

Dec 1969

Guidelines and Advice

Optimal Systemic Therapy for Early Female Breast Cancer

Status: In-Review
ID: 1-21

Sep 2014

Guidelines and Advice

Organizational Guideline for Gynecologic Oncology Services in Ontario

Status: In-Review
ID: 4-11

Dec 1969

Guidelines and Advice

Optimization of Surgical and Pathological Quality Performance in Radical Surgery for Colon and Rectal Cancer: Margins and Lymph Nodes

Status: Current
ID: 17-4
Version: 2

Nov 2016

Guidelines and Advice

Optimal Therapy for Patients Diagnosed with Multiple Myeloma and the Role of High-Dose Chemotherapy and Stem Cell Support

Status: Education and Information
ID: 6-6 Version 2
Version: 2

Jan 2012

Guidelines and Advice

Effective Teaching Strategies and Methods for Cancer Patient Education

Status: Current
ID: GL 20-2
Version: 2

Dec 1969

Guidelines and Advice

Extra-corporeal Photopheresis in the Management of Graft-Versus-Host Disease in Patients who Have Received Allogeneic Blood or Bone Marrow Transplants: Recommendations

Status: Current
ID: SCT 5

Dec 1969

Guidelines and Advice

Use of Preoperative Chemotherapy With or Without Postoperative Radiotherapy in Technically Resectable Stage IIIA Non-Small Cell Lung Cancer

Status: Archived
ID: 7-4
Version: 2

Dec 1969

Guidelines and Advice

Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib (Iressa®), Erlotinib (Tarceva®), Afatinib, Dacomitinib or Icotinib in the Treatment of Non–SmallCell Lung Cancer: A Clinical Practice Guideline

Status: In-Review
ID: 7-9
Version: 2

Dec 1969

Guidelines and Advice

Epirubicin, as a Single Agent or in Combination, for Metastatic Breast Cancer

Status: Archived
ID: 1-6

Sep 2011

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Exercise for People with Cancer

Organizational Standards for Diagnostic Assessment Programs

Establishing Comprehensive Cancer Patient Education Services

Optimal Systemic Therapy for Early Female Breast Cancer

Organizational Guideline for Gynecologic Oncology Services in Ontario

Optimization of Surgical and Pathological Quality Performance in Radical Surgery for Colon and Rectal Cancer: Margins and Lymph Nodes

Optimal Therapy for Patients Diagnosed with Multiple Myeloma and the Role of High-Dose Chemotherapy and Stem Cell Support

Effective Teaching Strategies and Methods for Cancer Patient Education

Extra-corporeal Photopheresis in the Management of Graft-Versus-Host Disease in Patients who Have Received Allogeneic Blood or Bone Marrow Transplants: Recommendations

Use of Preoperative Chemotherapy With or Without Postoperative Radiotherapy in Technically Resectable Stage IIIA Non-Small Cell Lung Cancer

Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib (Iressa®), Erlotinib (Tarceva®), Afatinib, Dacomitinib or Icotinib in the Treatment of Non–SmallCell Lung Cancer: A Clinical Practice Guideline

Epirubicin, as a Single Agent or in Combination, for Metastatic Breast Cancer

Pages